These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17466912)

  • 1. mTOR-inhibitors simultaneously inhibit proliferation and basal IL-6 synthesis of human coronary artery endothelial cells.
    Schreml S; Lehle K; Birnbaum DE; Preuner JG
    Int Immunopharmacol; 2007 Jun; 7(6):781-90. PubMed ID: 17466912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predominant inhibition of interleukin-6 synthesis in patient-specific endothelial cells by mTOR inhibitors below a concentration range where cell proliferation is affected and mitotic arrest takes place.
    Lehle K; Birnbaum DE; Preuner JG
    Transplant Proc; 2005; 37(1):159-61. PubMed ID: 15808580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR inhibitors and calcineurin inhibitors do not affect adhesion molecule expression of human macro- and microvascular endothelial cells.
    Lehle K; Schreml S; Kunz-Schughart LA; Rupprecht L; Birnbaum DE; Schmid C; Preuner JG
    J Vasc Res; 2008; 45(4):333-42. PubMed ID: 18319592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone induces human leukocyte antigen-g expression in vascular endothelial and smooth muscle cells.
    Sheshgiri R; Rao V; Tumiati LC; Xiao R; Prodger JL; Badiwala M; Librach C; Delgado DH
    Circulation; 2008 Sep; 118(14 Suppl):S58-64. PubMed ID: 18824770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling.
    Hafizi S; Mordi VN; Andersson KM; Chester AH; Yacoub MH
    Vascul Pharmacol; 2004; 41(4-5):167-76. PubMed ID: 15607500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin inhibits release of tumor necrosis factor-alpha from human vascular smooth muscle cells.
    Adkins JR; Castresana MR; Wang Z; Newman WH
    Am Surg; 2004 May; 70(5):384-7; discussion 387-8. PubMed ID: 15156944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STAT6 mediates apoptosis of human coronary arterial endothelial cells by interleukin-13.
    Nishimura Y; Nitto T; Inoue T; Node K
    Hypertens Res; 2008 Mar; 31(3):535-41. PubMed ID: 18497474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy.
    Keller K; Daniel C; Schöcklmann H; Endlich KH; Kerjaschki D; Johnson RJ; Hugo C
    Nephrol Dial Transplant; 2006 Oct; 21(10):2724-35. PubMed ID: 16861242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
    Vogelbacher R; Wittmann S; Braun A; Daniel C; Hugo C
    Transplantation; 2007 Dec; 84(11):1492-9. PubMed ID: 18091526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of injuries pulmonary arterial endothelial cell induced by endotoxin on proliferation of pulmonary artery smooth muscle cells and interference effect of bone morphogenetic protein-2].
    Pei L; Shan SM; Sun XY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(1):40-5. PubMed ID: 18346379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell proliferation.
    Rupertus K; Dahlem C; Menger MD; Schilling MK; Kollmar O
    Ann Surg Oncol; 2009 Sep; 16(9):2629-37. PubMed ID: 19551445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pleiotropic effects of mTor inhibitors.
    Ponticelli C
    J Nephrol; 2004; 17(6):762-8. PubMed ID: 15593048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human leukocyte histocompatibility antigen class II-induced cytokines from human gingival fibroblasts promote proliferation of human umbilical vein endothelial cells: potential association with enhanced angiogenesis in chronic periodontal inflammation.
    Okada Y; Meguro M; Ohyama H; Yoshizawa S; Takeuchi-Hatanaka K; Kato N; Matsushita S; Takashiba S; Nishimura F
    J Periodontal Res; 2009 Feb; 44(1):103-9. PubMed ID: 19515021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of endothelial cell differentiation and proinflammatory cytokine production during angiogenesis by allyl isothiocyanate and phenyl isothiocyanate.
    Thejass P; Kuttan G
    Integr Cancer Ther; 2007 Dec; 6(4):389-99. PubMed ID: 18048887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer.
    Papewalis C; Wuttke M; Schinner S; Willenberg HS; Baran AM; Scherbaum WA; Schott M
    Horm Metab Res; 2009 Oct; 41(10):752-6. PubMed ID: 19513966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
    Manegold PC; Paringer C; Kulka U; Krimmel K; Eichhorn ME; Wilkowski R; Jauch KW; Guba M; Bruns CJ
    Clin Cancer Res; 2008 Feb; 14(3):892-900. PubMed ID: 18245553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.